Abstract
Background: Induction chemotherapy (ICT) has become an initial treatment for late-stage hypopharyngeal squamous cell carcinoma (SCC); however, there are no data regarding ICT sensitivity for this population. Objective: This study investigated the predictive value of various inflammation markers for ICT responses in hypopharyngeal SCC. Methods: The data from 72 patients who received initial ICT treatment were obtained and associations between pretreatment inflammation markers and overall responses to ICT were calculated. Results: According to receiver operating characteristic curves, pretreatment lymphocyte count (PLC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) achieved diagnostic accuracy for overall responses to ICT. These indicators were classified into two groups according to their cut-off values. Overall response rates were significantly higher in the low PLC (p < 0.01), high NLR (p = 0.035), and high PLR (p = 0.012) groups. Conclusion: Our results showed that low PLC, high NLR, and high PLR are predictors of positive responses to ICT in hypopharyngeal SCC patients.
References
1.
Hoffmann TK1
, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, et al. Response Evaluation in Head and Neck Oncology: Definition and Prediction. ORL J Otorhinolaryngol Relat Spec. 2017
;79(1--2):14--23.2.
Lefebvre
JL
, Andry
G
, Chevalier
D
, Luboinski
B
, Collette
L
, Traissac
L
, et al.; EORTC Head and Neck Cancer Group
. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891
. Ann Oncol
. 2012
Oct
;23
(10
):2708
–14
.
[PubMed]
0923-75343.
Granados-García
M
, Aguilar-Ponce
JL
, Maldonado-Magos
F
, De la Garza-Salazar
JG
. Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab
. ORL J Otorhinolaryngol Relat Spec
. 2016
;78
(6
):320
–33
.
[PubMed]
0301-15694.
Zenner
HP
. Individual Biomarkers Using Molecular Personalized Medicine Approaches.
ORL J Otorhinolaryngol Relat Spec. 2017
;79(1--2):7--13. 5.
Ku
JH
, Kang
M
, Kim
HS
, Jeong
CW
, Kwak
C
, Kim
HH
. The prognostic value of pretreatment of systemic inflammatory responses in patients with urothelial carcinoma undergoing radical cystectomy
. Br J Cancer
. 2015
Feb
;112
(3
):461
–7
.
[PubMed]
0007-09206.
Krenn-Pilko
S
, Langsenlehner
U
, Thurner
EM
, Stojakovic
T
, Pichler
M
, Gerger
A
, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients
. Br J Cancer
. 2014
May
;110
(10
):2524
–30
.
[PubMed]
0007-09207.
Lee
S
, Oh
SY
, Kim
SH
, Lee
JH
, Kim
MC
, Kim
KH
, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
. BMC Cancer
. 2013
Jul
;13
(1
):350
.
[PubMed]
1471-24078.
Kano
S
, Homma
A
, Hatakeyama
H
, Mizumachi
T
, Sakashita
T
, Kakizaki
T
, et al. Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer
. Head Neck
. 2017
Feb
;39
(2
):247
–53
.
[PubMed]
1043-30749.
Eisenhauer
EA
, Therasse
P
, Bogaerts
J
, Schwartz
LH
, Sargent
D
, Ford
R
, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
. Eur J Cancer
. 2009
Jan
;45
(2
):228
–47
.
[PubMed]
0959-804910.
Zou
ZY
, Liu
HL
, Ning
N
, Li
SY
, Du
XH
, Li
R
. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer
. Oncol Lett
. 2016
Mar
;11
(3
):2241
–8
.
[PubMed]
1792-107411.
Valero
C
, Pardo
L
, López
M
, García
J
, Camacho
M
, Quer
M
, et al. Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer
. Head Neck
. 2017
Feb
;39
(2
):219
–26
.
[PubMed]
1043-307412.
Hsueh
C
, Tao
L
, Zhang
M
, Cao
W
, Gong
H
, Zhou
J
, et al. The prognostic value of preoperative neutrophils, platelets, lymphocytes, monocytes and calculated ratios in patients with laryngeal squamous cell cancer
. Oncotarget
. 2017
Mar
;8
(36
):60514
–27
.
[PubMed]
1949-255313.
Partlová
S
, Bouček
J
, Kloudová
K
, Lukešová
E
, Zábrodský
M
, Grega
M
, et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
. OncoImmunology
. 2015
Jan
;4
(1
):e965570
.
[PubMed]
2162-401114.
Qian
Y
, Tao
J
, Li
X
, Chen
H
, Lu
Q
, Yang
J
, et al. Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
. OncoTargets Ther
. 2018
Mar
;11
:1423
–32
.
[PubMed]
1178-693015.
Sun
H
, Hu
P
, Du
J
, Wang
X
. Predictive value of inflammatory indexes on the chemotherapeutic response in patients with unresectable lung cancer: A retrospective study
. Oncol Lett
. 2018
Mar
;15
(3
):4017
–25
.
[PubMed]
1792-107416.
Chen
Y
, Chen
K
, Xiao
X
, Nie
Y
, Qu
S
, Gong
C
, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study
. BMC Cancer
. 2016
May
;16
(1
):320
.
[PubMed]
1471-240717.
Sato
H
, Tsubosa
Y
, Kawano
T
. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer
. World J Surg
. 2012
Mar
;36
(3
):617
–22
.
[PubMed]
0364-231318.
Suppan
C
, Bjelic-Radisic
V
, La Garde
M
, Groselj-Strele
A
, Eberhard
K
, Samonigg
H
, et al. Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy
. BMC Cancer
. 2015
Dec
;15
(1
):1027
.
[PubMed]
1471-240719.
Yeung
J
, Li
W
, Holinstat
M
. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases
. Pharmacol Rev
. 2018
Jul
;70
(3
):526
–48
.
[PubMed]
0031-699720.
Leibowitz-Amit
R
, Israel
A
, Gal
M
, Atenafu
EA
, Symon
Z
, Portnoy
O
, et al. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer
. Clin Oncol (R Coll Radiol)
. 2016
Dec
;28
(12
):790
–6
.
[PubMed]
0936-6555© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
